Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 1 12Phase 1/2 9Phase NA 8Phase 3 3Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 161Neoplasms 95Prostatic Neoplasms 86Glioblastoma 76Multiple Myeloma 66Pancreatic Neoplasms 64Glioma 62Brain Neoplasms 56Lung Neoplasms 46Carcinoma, Hepatocellular 45Melanoma 44Head and Neck Neoplasms 43Recurrence 42Carcinoma, Non-Small-Cell Lung 41Leukemia, Myeloid, Acute 40Colorectal Neoplasms 39Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 29Lymphoma 29Carcinoma, Renal Cell 28Polycystic Ovary Syndrome 27Stomach Neoplasms 24Hematologic Neoplasms 23Sarcoma 22Lymphoma, B-Cell 22Endometrial Neoplasms 20Uterine Cervical Neoplasms 19

Interventions

pembrolizumab 1cemiplimab 1avelumab 1Nivolumab 1Ipilimumab 1Immune Checkpoint Inhibitors 1Exercise 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Carcinoma, Merkel Cell × Clear all
NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡